01
Separate maturity from hype
See whether a claim rests on established clinical evidence, early human research, preclinical biology, or inadequate support.
FREE 2026 EVIDENCE GUIDE
21 therapy/program entries. One map of what’s established, emerging, and still uncertain.
Go beyond headline weight-loss percentages. Compare evidence maturity, measured outcomes, regulatory status, and the questions the research has not answered yet.
Source-labeledM0–M5 maturityNo hype ranking
Get the free Evidence Map
Immediate PDF access · Study-dose context, not self-use protocols
WHAT THE MAP HELPS YOU SEE
A clearer way to read a fast-moving field.
02
Compare the right outcomes
Keep scale weight, fat mass, lean mass, skeletal muscle, strength, and function from being treated as interchangeable.
03
Understand what remains uncertain
See where regulatory status, trial design, source quality, and missing body-composition data limit the conclusion.
PROPRIETARY EVIDENCE LENS
Evidence Maturity Strength, from M0 to M5.
A therapy can have mature evidence for one outcome and weak evidence for another. RecompSignal keeps overall maturity, outcome-specific evidence, and source quality separate.
Explore the full methodology →M5Established
M4Advanced clinical
M3Clinical
M2Preliminary human
M1Preclinical
M0Unsupported
DOWNLOAD THE FREE GUIDE
See which therapies have the strongest evidence—not just the biggest headline.
- 21 named therapy and research-program entries
- Evidence Maturity Strength from M0–M5
- Weight, fat, lean-mass and function outcomes kept separate
- Regulatory status, source labels and uncertainty notes
Educational research, not medical advice. The map does not recommend a therapy, provide dosing protocols, or direct readers to sourcing.
BUILT FOR CLARITY
Evidence is more useful when the categories stay separate.
RecompSignal distinguishes clinical development, outcome evidence, source quality, regulatory status, and uncertainty—so an impressive number is not mistaken for a complete answer.
Evidence Map v1.1 · September 19, 2026. Covers 21 named therapy/program entries, including 17 detailed study summaries and four limited-evidence/watchlist entries. Study doses are research context, not treatment instructions.